<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <title>Leah_Kleylein's blog</title>
  <link rel="alternate" type="text/html" href="http://community.viewpointquantum.com/blog/6"/>
  <link rel="self" type="application/atom+xml" href="http://community.viewpointquantum.com/blog/6/atom/feed"/>
  <id>http://community.viewpointquantum.com/blog/6/atom/feed</id>
  <updated>2008-12-17T09:32:37-05:00</updated>
  <entry>
    <title>FDA creates Guidance on ISS/ISE Placement</title>
    <link rel="alternate" type="text/html" href="http://community.viewpointquantum.com/node/125" />
    <id>http://community.viewpointquantum.com/node/125</id>
    <published>2009-04-21T10:34:38-04:00</published>
    <updated>2009-04-21T10:34:38-04:00</updated>
    <author>
      <name>Leah_Kleylein</name>
    </author>
    <category term="FDA" />
    <category term="guidance" />
    <category term="ISE" />
    <category term="ISE" />
    <category term="ISS" />
    <category term="ISS" />
    <summary type="html"><![CDATA[<div dir="ltr"><span style="font-size: small;"><span style="font-family: verdana,geneva;">This morning I saw that FDA put out an actual guidance  on placement of the ISS/ISE. </span></span></div>
<div dir="ltr"><span style="font-size: small;"><span style="font-family: verdana,geneva;"><br /></span></span></div>
    ]]></summary>
    <content type="html"><![CDATA[<div dir="ltr"><span style="font-size: small;"><span style="font-family: verdana,geneva;">This morning I saw that FDA put out an actual guidance  on placement of the ISS/ISE. </span></span></div>
<div dir="ltr"><span style="font-size: small;"><span style="font-family: verdana,geneva;"><br /></span></span></div>
<div dir="ltr"><span style="font-size: small;"><span style="font-family: verdana,geneva;">Before they had the webpage (and still reference  it in the guidance): <a href="http://www.fda.gov/cder/regulatory/ersr/ISS_ISE_clarification.htm" target="_blank">http://www.fda.gov/cder/regulatory/ersr/ISS_ISE_clarification.htm</a></span></span></div>
<div dir="ltr"><span style="font-size: small;"><span style="font-family: verdana,geneva;"><br /></span></span></div>
<div dir="ltr"><span style="font-size: small;"><span style="font-family: verdana,geneva;">The guidance can be found at:  <a href="http://www.fda.gov/cder/guidance/8524fnl.pdf" target="_blank">http://www.fda.gov/cder/guidance/8524fnl.pdf</a></span></span></div>
<div dir="ltr"><span style="font-size: small;"><span style="font-family: verdana,geneva;"><br /></span></span></div>
<div dir="ltr"><span style="font-size: small;"><span style="font-family: verdana,geneva;">They've reproduced the same table from the  webpage in the guidance (as Table 1) and then just spent time talking about it  all.</span></span></div>
<div dir="ltr"><span style="font-size: small;"><span style="font-family: verdana,geneva;"><br /></span></span></div>
<div dir="ltr"><span style="font-size: small;"><span style="font-family: verdana,geneva;">They also describe the exception  case:</span></span></div>
<div dir="ltr"><span style="font-size: small;"><span style="font-family: verdana,geneva;"><strong> </strong></p>
<p align="left"><strong>C. Exceptions </strong></p>
<p>There may be situations in which sections 2.7.3, Summary of Clinical  Efficacy, and 2.7.4, Summary of Clinical Safety, would be sufficiently detailed  to serve as the narrative portion of the ISE and ISS, respectively, while still  concise enough to meet the suggested size limitations for Module 2. This  situation is rare but can occur if the application is small and consists of a  single study or a number of small studies. In our experience, the narrative  portion of the ISE often is more amenable for inclusion in Module 2 than is the  ISS. In such situations, the ISE and ISS can be split across Module 2 and Module  5, with the narrative portion located in section 2.7.3 or 2.7.4 and the  appendices of tables, figures, and datasets located in section 5.3.5.3. If the  ISE or ISS is split across modules in this way, it is critical to include a  clear explanation of where the parts are located. This explanation should be  placed both in Module 2 (section 2.7.3 or 2.7.4) and in Module 5 (section  5.3.5.3).</p>
<p></span></span></div>
<div dir="ltr"><span style="font-size: small;"><span style="font-family: verdana,geneva;"><br /></span></span></div>
<div dir="ltr"><span style="font-size: small;"><span style="font-family: verdana,geneva;">Finally, they give some examples of real  life cases that have been taken from various FDA presentations to the  industry.</span></span></div>
<div dir="ltr"><span style="font-size: small;"><span style="font-family: verdana,geneva;"><br /></span></span></div>
<div dir="ltr"><span style="font-size: small;"><span style="font-family: verdana,geneva;">Nothing major, but good to know this now  exists.</span></span></div>
<p> </p>
    ]]></content>
  </entry>
  <entry>
    <title>Swissmedic to accept eCTD starting in 2010</title>
    <link rel="alternate" type="text/html" href="http://community.viewpointquantum.com/node/124" />
    <id>http://community.viewpointquantum.com/node/124</id>
    <published>2009-03-23T09:18:10-04:00</published>
    <updated>2009-03-23T09:18:10-04:00</updated>
    <author>
      <name>Leah_Kleylein</name>
    </author>
    <category term="eCTD" />
    <category term="Swissmedic" />
    <category term="Swissmedic" />
    <summary type="html"><![CDATA[<p><span style="font-size: medium;"><span style="font-family: verdana,geneva;">The Swiss Health Authority Swissmedic will accept applications in eCTD format starting in January 2010.  They have an announcement for all this on their website, but it doesn't do you much good unless you read German, which sadly, I cannot.  <br /></span></span></p>
<p><span style="font-size: medium;"><span style="font-family: verdana,geneva;"><a href="http://www.swissmedic.ch/aktuell/00003/00870/index.html?lang=en">http://www.swissmedic.ch/aktuell/00003/00870/index.html?lang=en</a><br /></span></span></p>
    ]]></summary>
    <content type="html"><![CDATA[<p><span style="font-size: medium;"><span style="font-family: verdana,geneva;">The Swiss Health Authority Swissmedic will accept applications in eCTD format starting in January 2010.  They have an announcement for all this on their website, but it doesn't do you much good unless you read German, which sadly, I cannot.  <br /></span></span></p>
<p><span style="font-size: medium;"><span style="font-family: verdana,geneva;"><a href="http://www.swissmedic.ch/aktuell/00003/00870/index.html?lang=en">http://www.swissmedic.ch/aktuell/00003/00870/index.html?lang=en</a><br /></span></span></p>
<p> </p>
<p><span style="font-size: medium;"><span style="font-family: verdana,geneva;">It's not that hard to figure out, but it's better not to to take chances.  eCTDblog.com has kindly put it all through a google translator and voila, English!  The sentence structure is still German though, and that's kind of cool.<br /></span></span></p>
<p><span style="font-size: medium;"><span style="font-family: verdana,geneva;"><a href="http://www.ectdblog.com/2009/03/swissmedic-ectd-announcement.html">http://www.ectdblog.com/2009/03/swissmedic-ectd-announcement.html</a><br /></span></span></p>
<p> </p>
<p><span style="font-size: medium;"><span style="font-family: verdana,geneva;">For those of you that don't care about all this language stuff and just want the information, here are the highlights:</span></span></p>
<p><span style="font-size: medium;"><span style="font-family: verdana,geneva;"><span style="text-decoration: underline;">January 2009</span> - Project Kickoff</span></span></p>
<p><span style="font-size: medium;"><span style="font-family: verdana,geneva;"><span style="text-decoration: underline;">March 2009 and on</span> - Publication of Project information on Swissmedic webpage</span></span></p>
<p><span style="font-size: medium;"><span style="font-family: verdana,geneva;"><span style="text-decoration: underline;">July 2009</span> - First version of Swiss eCTD specification and guidance will be available</span></span></p>
<p><span style="font-size: medium;"><span style="font-family: verdana,geneva;"><span style="text-decoration: underline;">October 2009</span> - Final version of Swiss eCTD specification and guidance available</span></span></p>
<p><span style="font-size: medium;"><span style="font-family: verdana,geneva;"><span style="text-decoration: underline;">January 2010</span> - Applications in eCTD format that are of an acceptable submission type will be accepted</span></span></p>
<p> </p>
<p> </p>
<p> </p>
<p> </p>
    ]]></content>
  </entry>
  <entry>
    <title>RPS Codes Posted on NCI Website</title>
    <link rel="alternate" type="text/html" href="http://community.viewpointquantum.com/node/123" />
    <id>http://community.viewpointquantum.com/node/123</id>
    <published>2009-03-20T07:42:08-04:00</published>
    <updated>2009-03-20T07:42:09-04:00</updated>
    <author>
      <name>Leah_Kleylein</name>
    </author>
    <category term="RPS" />
    <category term="RPS" />
    <summary type="html"><![CDATA[<p><span style="font-size: medium;"><span style="font-family: verdana,geneva;">A step in the right direction.....codes for RPS have been posted on the NCI website.  It's not pretty yet, but it's there.  However, right now, the codes provided are only the table of contents sections for ICH’s Common Technical Document (Modules 2-5) and the US FDA’s regional table of contents (Module 1).</span></span></p>
<p> </p>
    ]]></summary>
    <content type="html"><![CDATA[<p><span style="font-size: medium;"><span style="font-family: verdana,geneva;">A step in the right direction.....codes for RPS have been posted on the NCI website.  It's not pretty yet, but it's there.  However, right now, the codes provided are only the table of contents sections for ICH’s Common Technical Document (Modules 2-5) and the US FDA’s regional table of contents (Module 1).</span></span></p>
<p> </p>
<p><span style="font-size: large;"><span style="font-size: medium;"><span style="font-family: verdana,geneva;">Here is where an explanation is posted by Jason Rock:</span></span></span></p>
<p><span style="font-size: medium;"><span style="font-family: verdana,geneva;"><a href="http://theectdsummit.com/summit/?p=299">http://theectdsummit.com/summit/?p=299</a></span></span></p>
<p> </p>
<p><span style="font-size: medium;"><span style="font-family: verdana,geneva;">Here you can go straight to the codes:<br /></span></span></p>
<p><span style="font-size: medium;"><span style="font-family: verdana,geneva;"><a href="http://nciterms.nci.nih.gov/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C79148&amp;bookmarktag=1">http://nciterms.nci.nih.gov/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C79148&amp;bookmarktag=1</a></span></span></p>
<p> </p>
<p><span style="font-size: medium;"><span style="font-family: verdana,geneva;"><br /></span></span></p>
    ]]></content>
  </entry>
  <entry>
    <title>FDA Inspections and the Dreaded 483</title>
    <link rel="alternate" type="text/html" href="http://community.viewpointquantum.com/node/120" />
    <id>http://community.viewpointquantum.com/node/120</id>
    <published>2009-02-25T11:27:16-05:00</published>
    <updated>2009-02-25T11:27:16-05:00</updated>
    <author>
      <name>Leah_Kleylein</name>
    </author>
    <category term="483" />
    <category term="483" />
    <category term="FDA" />
    <summary type="html"><![CDATA[<p><span style="font-size: small;"><span style="font-family: verdana,geneva;">There is a nice brief discussion of what a 483 is (in case you are dying to know) at the path below, along with a link to some suggestions that FDA has put out there on how to respond to one if you get one.</span></span></p>
<p><span style="font-family: verdana,geneva;"><a href="http://www.eyeonfda.com/eye_on_fda/2009/02/fda-presentation-on-responses-to-483s.html" target="_blank">http://www.eyeonfda.com/eye_on_fda/2009/02/fda-presentation-on-responses-to-483s.html</a></span></p>
    ]]></summary>
    <content type="html"><![CDATA[<p><span style="font-size: small;"><span style="font-family: verdana,geneva;">There is a nice brief discussion of what a 483 is (in case you are dying to know) at the path below, along with a link to some suggestions that FDA has put out there on how to respond to one if you get one.</span></span></p>
<p><span style="font-family: verdana,geneva;"><a href="http://www.eyeonfda.com/eye_on_fda/2009/02/fda-presentation-on-responses-to-483s.html" target="_blank">http://www.eyeonfda.com/eye_on_fda/2009/02/fda-presentation-on-responses-to-483s.html</a></span></p>
    ]]></content>
  </entry>
  <entry>
    <title>Guidances CDER is Planning for 2009</title>
    <link rel="alternate" type="text/html" href="http://community.viewpointquantum.com/node/119" />
    <id>http://community.viewpointquantum.com/node/119</id>
    <published>2009-02-10T09:00:48-05:00</published>
    <updated>2009-02-10T09:00:48-05:00</updated>
    <author>
      <name>Leah_Kleylein</name>
    </author>
    <category term="CDER" />
    <category term="guidance" />
    <summary type="html"><![CDATA[<p><span style="font-size: small;">CDER has put out their list for 2009 of <strong>planned </strong>guidances.  The few that relate directly (or indirectly) to Regulatory Operations are:</span></p>
    ]]></summary>
    <content type="html"><![CDATA[<p><span style="font-size: small;">CDER has put out their list for 2009 of <strong>planned </strong>guidances.  The few that relate directly (or indirectly) to Regulatory Operations are:</span></p>
<ul>
<li><span style="font-size: small;">Providing Regulatory Submissions in Electronic Format – Analysis Datasets and Documentation</span></li>
<li><span style="font-size: small;">Submission of Summary Bioequivalence Data for ANDAs</span></li>
<li><span style="font-size: small;">IND Safety Reporting</span></li>
<li><span style="font-size: small;">Content and Format of the Clinical Pharmacology Section (Labeling)<br /></span></li>
<li><span style="font-size: small;">Drug Names and Dosage Forms (Labeling)<br /></span></li>
</ul>
<p><span style="font-size: small;">The entire list can be found here:  <a href="http://www.fda.gov/cder/guidance/CY09.pdf" target="_blank">http://www.fda.gov/cder/guidance/CY09.pdf</a></span></p>
    ]]></content>
  </entry>
  <entry>
    <title>Australian eCTD Guidance</title>
    <link rel="alternate" type="text/html" href="http://community.viewpointquantum.com/node/117" />
    <id>http://community.viewpointquantum.com/node/117</id>
    <published>2009-01-19T09:47:30-05:00</published>
    <updated>2009-01-19T09:47:30-05:00</updated>
    <author>
      <name>Leah_Kleylein</name>
    </author>
    <category term="australia" />
    <category term="australia" />
    <category term="eCTD" />
    <category term="guidance" />
    <category term="module-1" />
    <category term="module-1" />
    <summary type="html"><![CDATA[<p><span style="font-size: small;"><span style="font-family: verdana,geneva;">Australia has put out some updated guidance and draft guidance on eCTD.  There is now a version 2.1 of the AU Module 1 Specification, and a draft version 1.5 of their guidance on submissions in eCTD format.  Both can be found on the TGA's website, the link is below.  Happy reading!</span></span></p>
<p><span style="font-size: small;"><span style="font-family: verdana,geneva;"><a href="http://www.tga.gov.au/docs/html/eugctd.htm" target="_blank">http://www.tga.gov.au/docs/html/eugctd.htm</a></span></span></p>
    ]]></summary>
    <content type="html"><![CDATA[<p><span style="font-size: small;"><span style="font-family: verdana,geneva;">Australia has put out some updated guidance and draft guidance on eCTD.  There is now a version 2.1 of the AU Module 1 Specification, and a draft version 1.5 of their guidance on submissions in eCTD format.  Both can be found on the TGA's website, the link is below.  Happy reading!</span></span></p>
<p><span style="font-size: small;"><span style="font-family: verdana,geneva;"><a href="http://www.tga.gov.au/docs/html/eugctd.htm" target="_blank">http://www.tga.gov.au/docs/html/eugctd.htm</a></span></span></p>
<p> </p>
    ]]></content>
  </entry>
  <entry>
    <title>Hungary and the eCTD</title>
    <link rel="alternate" type="text/html" href="http://community.viewpointquantum.com/node/116" />
    <id>http://community.viewpointquantum.com/node/116</id>
    <published>2009-01-05T09:19:33-05:00</published>
    <updated>2009-01-05T09:19:33-05:00</updated>
    <author>
      <name>Leah_Kleylein</name>
    </author>
    <category term="eCTD" />
    <category term="hungary" />
    <category term="hungary" />
    <summary type="html"><![CDATA[<p>Welcome back to work everyone!!!  I hope that you all enjoy a happy and prosperous 2009, we certainly all deserve it I think after that mess of a last year.  Anyway, back to work....</p>
    ]]></summary>
    <content type="html"><![CDATA[<p>Welcome back to work everyone!!!  I hope that you all enjoy a happy and prosperous 2009, we certainly all deserve it I think after that mess of a last year.  Anyway, back to work....</p>
<p>I found a link to a presentation on another <a href="http://theectdsummit.blogspot.com/2008/12/more-news-and-updates-from-eu-agencies.html" target="_blank">blog </a>that was by Dr. Gergely Zajzon of the Hungarian health authority on their status in using eCTDs.  Hungary was an early adopter of eCTD and has been actively supporting it at various conferences for the past few years.  The link below is to a presentation given last fall that lists some of the data around eCTDs received by Hungary, what they believe the positives are in reviewing eCTD and their work in digitizing the already received submissions.</p>
<p><a href="http://www.topra.org/files/assets/sym2008/TOPRA_Gergely_Zajzon_eSubmissions_in_Hungary.pdf" target="_blank">http://www.topra.org/files/assets/sym2008/TOPRA_Gergely_Zajzon_eSubmissions_in_Hungary.pdf</a></p>
    ]]></content>
  </entry>
  <entry>
    <title>December and RegOps</title>
    <link rel="alternate" type="text/html" href="http://community.viewpointquantum.com/node/115" />
    <id>http://community.viewpointquantum.com/node/115</id>
    <published>2008-12-17T07:39:37-05:00</published>
    <updated>2008-12-17T09:32:37-05:00</updated>
    <author>
      <name>Leah_Kleylein</name>
    </author>
    <category term="submissions" />
    <summary type="html"><![CDATA[<p class="MsoNormal"><span style="font-size: small;"><span style="font-family: arial,helvetica,sans-serif;">This is my favorite time of year, I admit it. I love Christmas and the holidays, garlands and lights on everything, sugary snacks and liquor abounding.</span></span></p>
<p class="MsoNormal"><!--[if !supportEmptyParas]--> <!--[endif]--></p>
    ]]></summary>
    <content type="html"><![CDATA[<p class="MsoNormal"><span style="font-size: small;"><span style="font-family: arial,helvetica,sans-serif;">This is my favorite time of year, I admit it. I love Christmas and the holidays, garlands and lights on everything, sugary snacks and liquor abounding.</span></span></p>
<p class="MsoNormal"><!--[if !supportEmptyParas]--> <!--[endif]--></p>
<p class="MsoNormal"><span style="font-size: small;"><span style="font-family: arial,helvetica,sans-serif;">But being in submission publishing always made it a little tough to fully enjoy the buildup because there are always those end of year submissions. They are in addition to the end of quarter, end of month, end of week, end of day submissions of course. But end of year was all of those rolled into one; so you can’t really relax until that last submission is out the door. THEN your holidays start.</span></span></p>
<p class="MsoNormal"><!--[if !supportEmptyParas]--> <!--[endif]--></p>
<p class="MsoNormal"><span style="font-size: small;"><span style="font-family: arial,helvetica,sans-serif;">One year I was working on an electronic IND that was to be submitted on December 18<sup>th</sup>. The protocol (including list of references!) was not finalized until the day before. I remember just sitting at my desk, with my little Christmas tree, and Christmas music streaming on my computer, pounding away at finishing up that IND. I’m grateful for that streaming Christmas music, I know it’s a waste of bandwidth, but it cheered me and kept me going. Also cheering were the gifts of vodka from my CMC co-workers, who felt guilty for their lateness as well. Not that we had liquor at the workplace, of course. Because that would be wrong.</span></span></p>
<p class="MsoNormal"><!--[if !supportEmptyParas]--> <!--[endif]--></p>
<p class="MsoNormal"><span style="font-size: small;"><span style="font-family: arial,helvetica,sans-serif;">It’s been a couple years now that I haven’t actually been in the midst of end of year submissions – either on the periphery “managing”, or just not involved. And because of that, I get to take loads of vacation days at the end of the year. I can’t even begin to explain my guilt at this!! I can’t shake it though.  I feel like I am some jerky person lolling around when I know, I KNOW somewhere someone is working on a submission for December 23<sup>rd</sup> or 31<sup>st</sup> and I should be helping them.</span></span></p>
<p class="MsoNormal"><!--[if !supportEmptyParas]--> <!--[endif]--></p>
<p class="MsoNormal"><span style="font-size: small;"><span style="font-family: arial,helvetica,sans-serif;">I even still have a hard time with end of day and end of week meetings. There’s nothing more annoying than getting some meeting scheduled when you have 3 submissions to go out that day and you’re told your presence is mandatory. So for years, I made sure that when I scheduled meetings that involved RegOps people, it was morning or early afternoon, and certainly not on a Friday. Of course, I don’t need to worry about this in my current position, and yet I still get annoyed at late day and end-of-week meetings. Okay, not annoyed, but you know what I mean, my first knee-jerk reaction is hey, I’m going to need that time….oh wait, no I don’t. I wonder if I’ll ever get past that, or if it’s so ingrained after decades, it’s not going anywhere. </span></span></p>
<p class="MsoNormal"><!--[if !supportEmptyParas]--> <!--[endif]--></p>
<p class="MsoNormal"><span style="font-size: small;"><span style="font-family: arial,helvetica,sans-serif;">I wonder if as we advance even more with the electronic publishing, will all this go away? Will the end-of-whatever rushes go away? Probably not, we’ll still have Reg Affairs folks who try to cram-in last minute submissions. You know who you are!  <img rel="lightbox" src="/community/modules/tinymce/tinymce/jscripts/tiny_mce/plugins/emotions/img/smiley-laughing.gif" alt="Laughing" title="Laughing" /><br /></span></span></p>
<p class="MsoNormal"><span style="font-size: small;"><span style="font-family: arial,helvetica,sans-serif;"> </span></span></p>
<p class="MsoNormal"><!--[if !supportEmptyParas]--> <!--[endif]--></p>
<p class="MsoNormal"><span style="font-size: small;"><span style="font-family: arial,helvetica,sans-serif;">So, to all my former and current RegOps co-workers, my holiday wish for you is timely and accurate submissions. Whatever holidays you celebrate, I hope they are happy!!!</span></span></p>
<p> </p>
    ]]></content>
  </entry>
</feed>

